Dulaglutide vs TB-500
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideRecovery & Repair
TB-500- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.
- Half-Life
- ~5 days
- 2–3 hours
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 2–2.5 mg
- Frequency
- Once weekly
- Twice weekly
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Enhances muscle tissue regeneration
- Accelerates healing of wounds and injuries
- Reduces inflammation and pain
- Improves flexibility and mobility
- Promotes new blood vessel formation
- Supports hair growth and skin health
- May improve cardiac function after injury
- Systemic healing effect — works at distance from injection site
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Injection site discomfort
- Fatigue (rare)
- Headache (rare)
- Stacks With
- —
- —